The report noted that it was transmitted to 12 of 36 patients over the past two months, none of whom has gone overseas or got in contact with known cases of the variant.
This development raised concerns that the virus is more transmissible and more resistant to current Covid-19 vaccines, as shown in the research of the strain by British universities.
Cambridge University researcher Ravindra Gupta noted that those contracting E484K would “need to raise their antibody serums prevent cell infection, making the strain far deadlier than previous Coronavirus mutations,” he asserted.
“The strain can strengthen the virus and enable it bypass the body’s immune system,” said Warwick University virologist and oncology professor Lawrence Young in the United Kingdom.
“The E484K mutation can weaken the body’s immune system. This is potentially worse if an individual who [previously contracted Covid-19] contracted the virus again.”
The BMJ medical journal reported Novavax’s Covid-19 vaccine is only 60 percent effective against the Eek virus. The findings on E484K prompted the AstraZeneca pharmaceutical company to redesign its Covid-19 vaccine.
(Penulis : Haryanti Puspa Sari, Dian Erika Nugraheny, Sekar Langit Nariswari
Editor : Icha Rastika, Kristian Erdianto, Glori K. Wadrianto)